[go: up one dir, main page]

HK1029790A1 - Processes and intermediates for preparing anti-cancer compounds - Google Patents

Processes and intermediates for preparing anti-cancer compounds

Info

Publication number
HK1029790A1
HK1029790A1 HK01100595A HK01100595A HK1029790A1 HK 1029790 A1 HK1029790 A1 HK 1029790A1 HK 01100595 A HK01100595 A HK 01100595A HK 01100595 A HK01100595 A HK 01100595A HK 1029790 A1 HK1029790 A1 HK 1029790A1
Authority
HK
Hong Kong
Prior art keywords
intermediates
processes
preparing anti
cancer compounds
cancer
Prior art date
Application number
HK01100595A
Other languages
English (en)
Inventor
Richard Shelton Lehner
Timothy Norris
Dinos Paul Santafianos
Original Assignee
Pfizer Prod Inc
Osi Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc, Osi Pharm Inc filed Critical Pfizer Prod Inc
Publication of HK1029790A1 publication Critical patent/HK1029790A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
    • C22B15/00—Obtaining copper
    • C22B15/0002—Preliminary treatment
    • C22B15/0004—Preliminary treatment without modification of the copper constituent
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
    • C22B15/00—Obtaining copper
    • C22B15/0063—Hydrometallurgy
    • C22B15/0065—Leaching or slurrying
    • C22B15/0067—Leaching or slurrying with acids or salts thereof
    • C22B15/0071—Leaching or slurrying with acids or salts thereof containing sulfur
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P10/00—Technologies related to metal processing
    • Y02P10/20—Recycling

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Metallurgy (AREA)
  • Mechanical Engineering (AREA)
  • Materials Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK01100595A 1999-03-31 2001-01-27 Processes and intermediates for preparing anti-cancer compounds HK1029790A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12707299P 1999-03-31 1999-03-31

Publications (1)

Publication Number Publication Date
HK1029790A1 true HK1029790A1 (en) 2001-04-12

Family

ID=22428179

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01100595A HK1029790A1 (en) 1999-03-31 2001-01-27 Processes and intermediates for preparing anti-cancer compounds

Country Status (50)

Country Link
US (1) US6476040B1 (es)
EP (1) EP1044969B1 (es)
JP (2) JP3420549B2 (es)
KR (2) KR100430210B1 (es)
CN (2) CN1215061C (es)
AP (2) AP1265A (es)
AR (1) AR018705A1 (es)
AT (1) ATE348098T1 (es)
AU (2) AU781402B2 (es)
BG (1) BG65194B1 (es)
BR (1) BRPI0001486B8 (es)
CA (2) CA2302965C (es)
CO (1) CO5160273A1 (es)
CR (1) CR6165A (es)
CZ (1) CZ299426B6 (es)
DE (1) DE60032275T2 (es)
DK (1) DK1044969T3 (es)
DZ (1) DZ3030A1 (es)
EA (3) EA005892B1 (es)
EE (1) EE04589B1 (es)
EG (1) EG22506A (es)
ES (1) ES2278578T3 (es)
GE (1) GEP20022653B (es)
GT (1) GT200000037A (es)
HK (1) HK1029790A1 (es)
HR (1) HRP20000182B1 (es)
HU (1) HU227698B1 (es)
ID (1) ID25427A (es)
IL (2) IL135245A0 (es)
IS (1) IS2468B (es)
MA (1) MA25087A1 (es)
MY (1) MY136270A (es)
NO (2) NO321952B1 (es)
NZ (2) NZ503683A (es)
OA (1) OA11335A (es)
PA (1) PA8491901A1 (es)
PE (1) PE20001599A1 (es)
PL (1) PL339330A1 (es)
PT (1) PT1044969E (es)
RS (1) RS49836B (es)
SG (2) SG115536A1 (es)
SK (1) SK287339B6 (es)
SV (1) SV2002000047A (es)
TN (1) TNSN00064A1 (es)
TR (1) TR200000837A2 (es)
TW (1) TW553939B (es)
UA (2) UA70928C2 (es)
UY (1) UY26086A1 (es)
YU (1) YU13200A (es)
ZA (1) ZA200001586B (es)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
RU2264389C3 (ru) 2000-10-20 2018-06-01 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Азотсодержащие ароматические производные, их применение, лекарственное средство на их основе и способ лечения
WO2003000188A2 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel quinazolines and uses thereof
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
AU2003249212C1 (en) 2002-07-15 2011-10-27 Symphony Evolution, Inc. Receptor-type kinase modulators and methods of use
US7148231B2 (en) * 2003-02-17 2006-12-12 Hoffmann-La Roche Inc. [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph
EP1604665B1 (en) 2003-03-10 2011-05-11 Eisai R&D Management Co., Ltd. C-kit kinase inhibitor
JP5129957B2 (ja) 2003-07-03 2013-01-30 ミリアド ジェネティクス， インコーポレイテッド カスパーゼの活性化因子およびアポトーシスの誘発因子としての４−アリールアミノ−キナゾリン
US8309562B2 (en) * 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
MXPA06002964A (es) 2003-09-16 2006-06-14 Astrazeneca Ab Derivados de quinazolina como inhibidores de cinasa de tirosina.
SI2392564T1 (sl) 2003-09-26 2014-02-28 Exelixis, Inc. c-Met modulatorji in postopki uporabe
CN100450998C (zh) 2003-11-11 2009-01-14 卫材R&D管理有限公司 脲衍生物的制备方法
BRPI0510604B8 (pt) * 2004-05-06 2021-05-25 Warner Lambert Co composto 4-fenilamino-quinazolin-6-il-amida, seu uso e composição farmacêutica que o compreende composto 4-fenilamino-quinazolin-6-il-amida, seu uso e composição farmacêutica que o compreende
WO2006030826A1 (ja) 2004-09-17 2006-03-23 Eisai R & D Management Co., Ltd. 医薬組成物
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US7625911B2 (en) * 2005-01-12 2009-12-01 Mai De Ltd. Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion
CA2599115A1 (en) * 2005-02-28 2006-08-31 Eisai R & D Management Co., Ltd. Novel combinational use of sulfonamide compound
JP5066446B2 (ja) * 2005-08-01 2012-11-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を予測する方法
EP2281901B1 (en) 2005-08-02 2013-11-27 Eisai R&D Management Co., Ltd. Anti-tumour pharmaceutical composition with angiogenesis inhibitors
CA2627598C (en) * 2005-11-07 2013-06-25 Eisai R & D Management Co., Ltd. Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
EP1964837A4 (en) * 2005-11-22 2010-12-22 Eisai R&D Man Co Ltd Antitumor agent against multiple myeloma
CA2652442C (en) * 2006-05-18 2014-12-09 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
EP2044939A1 (en) * 2006-06-29 2009-04-08 Eisai R&D Management Co., Ltd. Therapeutic agent for liver fibrosis
CA2659307A1 (en) 2006-07-28 2008-01-31 Synthon B.V. Crystalline erlotinib
KR101472600B1 (ko) 2006-08-28 2014-12-15 에자이 알앤드디 매니지먼트 가부시키가이샤 미분화형 위암에 대한 항종양제
US8372856B2 (en) * 2006-10-27 2013-02-12 Synthon Bv Hydrates of erlotinib hydrochloride
KR20090108086A (ko) 2007-01-19 2009-10-14 에자이 알앤드디 매니지먼트 가부시키가이샤 췌장암 치료용 조성물
WO2008093855A1 (ja) 2007-01-29 2008-08-07 Eisai R & D Management Co., Ltd. 未分化型胃癌治療用組成物
PT2170844T (pt) * 2007-02-21 2016-08-05 Natco Pharma Ltd Novos polimorfos de cloridrato de erlotinib e método de preparação
NZ579997A (en) 2007-04-04 2012-08-31 Cipla Ltd PROCESS FOR PREPARATION OF N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
WO2009002538A2 (en) * 2007-06-25 2008-12-31 Plus Chemicals S.A. Amorphous erlotinib, processes for the preparation thereof, and processes to prepare additional forms of erlotinib
WO2009007984A2 (en) 2007-07-11 2009-01-15 Hetero Drugs Limited An improved process for erlotinib hydrochloride
US20090124642A1 (en) * 2007-08-23 2009-05-14 Augusto Canavesi Crystalline forms of Erlotinib HCI and formulations thereof
TW200927732A (en) * 2007-08-23 2009-07-01 Plus Chemicals S A Crystalline forms of erlotinib HCl and formulations thereof
US20090076042A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched erlotinib
CA2704000C (en) 2007-11-09 2016-12-13 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
WO2009096377A1 (ja) * 2008-01-29 2009-08-06 Eisai R & D Management Co., Ltd. 血管阻害物質とタキサンとの併用
CN102083801A (zh) * 2008-03-28 2011-06-01 康瑟特制药公司 喹唑啉衍生物和治疗方法
CA2730226A1 (en) * 2008-07-07 2010-01-14 Plus Chemicals Sa Crystalline forms of erlotinib base and erlotinib hcl
KR101132937B1 (ko) 2008-10-01 2012-04-06 주식회사종근당 Ｎ-(3-에티닐페닐)-6,7-비스(2-메톡시에톡시)-4-퀴나졸린아민 납실레이트 염
WO2010040212A1 (en) * 2008-10-08 2010-04-15 Apotex Pharmachem Inc. Processes for the preparation of erlotinib hydrochloride
CN110818633A (zh) 2009-01-16 2020-02-21 埃克塞里艾克西斯公司 一种苹果酸盐及其晶型
CN102438995B (zh) 2009-03-26 2014-12-17 兰贝克赛实验室有限公司 厄洛替尼或其药学上可接受的盐的制备工艺
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
EP2499118A2 (en) 2009-11-12 2012-09-19 Ranbaxy Laboratories Limited Processes for the preparation of erlotinib hydrochloride form a and erlotinib hydrochloride form b
WO2011068404A2 (en) 2009-12-02 2011-06-09 Ultimorphix Technologies B.V. Administration of n-(3-ethynylphenylamino)-6,7-bis(2- methoxyethoxy)-4-quinazolinamine mesylate salt by inhalation
CN102958523B (zh) 2010-06-25 2014-11-19 卫材R&D管理有限公司 使用具有激酶抑制作用的组合的抗肿瘤剂
CA2806273A1 (en) 2010-07-23 2012-03-08 Generics (Uk) Limited Pure erlotinib
IT1402029B1 (it) * 2010-10-14 2013-08-28 Italiana Sint Spa Procedimento per la preparazione di erlotinib
WO2012144463A1 (ja) 2011-04-18 2012-10-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
ES2705950T3 (es) 2011-06-03 2019-03-27 Eisai R&D Man Co Ltd Biomarcadores para predecir y valorar la capacidad de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
CN102267952B (zh) * 2011-06-21 2013-12-11 天津市汉康医药生物技术有限公司 喹唑啉类化合物、其制备方法和用途
CN103420924B (zh) * 2012-05-25 2016-08-31 浙江九洲药业股份有限公司 一种盐酸埃罗替尼晶型a的制备方法
WO2014037961A1 (en) 2012-09-04 2014-03-13 Shilpa Medicare Limited Crystalline erlotinib hydrochloride process
US9334239B2 (en) 2012-12-21 2016-05-10 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
WO2014118737A1 (en) 2013-01-31 2014-08-07 Ranbaxy Laboratories Limited Erlotinib salts
ES2687968T3 (es) 2013-05-14 2018-10-30 Eisai R&D Management Co., Ltd. Biomarcadores para pronosticar y evaluar la reactividad de sujetos con cáncer de endometrio a compuestos con lenvatinib
CN103333124B (zh) * 2013-05-28 2015-03-25 埃斯特维华义制药有限公司 一种制备盐酸厄洛替尼晶型f的方法
KR102329681B1 (ko) 2014-08-28 2021-11-23 에자이 알앤드디 매니지먼트 가부시키가이샤 고순도의 퀴놀린 유도체 및 이를 제조하는 방법
CA2908441A1 (en) 2014-10-28 2016-04-28 Cerbios-Pharma Sa Process for the preparation of erlotinib
US20180028662A1 (en) 2015-02-25 2018-02-01 Eisai R&D Management Co., Ltd. Method for Suppressing Bitterness of Quinoline Derivative
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
US11369623B2 (en) 2015-06-16 2022-06-28 Prism Pharma Co., Ltd. Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor
KR102587702B1 (ko) 2015-08-20 2023-10-12 에자이 알앤드디 매니지먼트 가부시키가이샤 종양 치료제
CN105884653A (zh) * 2016-06-08 2016-08-24 浙江汇能生物股份有限公司 一种埃罗替尼衍生物及其制备方法
CN106279585A (zh) * 2016-08-26 2017-01-04 宁波圣达精工智能科技有限公司 一种阻燃智能密集书架的制备方法
JP2020519576A (ja) 2017-05-16 2020-07-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 肝細胞癌の治療

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4747498A (en) * 1986-06-27 1988-05-31 Sunbeam Plastics Corporation Safety dispensing closure-container package
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
JP2657760B2 (ja) * 1992-07-15 1997-09-24 小野薬品工業株式会社 ４−アミノキナゾリン誘導体およびそれを含有する医薬品
DE69536015D1 (de) * 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
ATE237596T1 (de) 1996-02-13 2003-05-15 Astrazeneca Ab Chinazolinderivate und deren verwendung als vegf hemmer
PT885198E (pt) 1996-03-05 2002-06-28 Astrazeneca Ab Derivados de 4-anilinoquinazolina
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6225499B1 (en) 1997-07-14 2001-05-01 Catalytica Pharmaceuticals, Inc. Process for preparing aminoarylacetylenes
MEP42008A (en) 1998-04-29 2011-02-10 Osi Farmaceuticals Inc N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate

Also Published As

Publication number Publication date
ES2278578T3 (es) 2007-08-16
IS2468B (is) 2008-12-15
HUP0001353A3 (en) 2002-01-28
CZ299426B6 (cs) 2008-07-23
EE200000255A (et) 2000-12-15
PE20001599A1 (es) 2001-01-18
RS49836B (sr) 2008-08-07
BRPI0001486B1 (pt) 2019-01-29
EA005892B1 (ru) 2005-06-30
NO20001648D0 (no) 2000-03-30
BG104278A (en) 2001-08-31
KR100430209B1 (ko) 2004-05-03
BRPI0001486B8 (pt) 2021-05-25
NO321952B1 (no) 2006-07-24
JP2003176274A (ja) 2003-06-24
NZ503683A (en) 2001-09-28
CN1699350A (zh) 2005-11-23
CA2427221A1 (en) 2000-09-30
CN1215061C (zh) 2005-08-17
JP4074509B2 (ja) 2008-04-09
SK4442000A3 (en) 2000-10-09
KR20020084903A (ko) 2002-11-13
JP2000290262A (ja) 2000-10-17
EA200201244A1 (ru) 2003-04-24
NO20001648L (no) 2000-10-02
CA2302965A1 (en) 2000-09-30
EA200000274A3 (ru) 2003-02-27
TW553939B (en) 2003-09-21
PL339330A1 (en) 2000-10-09
KR100430210B1 (ko) 2004-05-03
MA25087A1 (fr) 2000-10-01
OA11335A (en) 2003-12-10
JP3420549B2 (ja) 2003-06-23
HRP20000182A2 (en) 2001-04-30
GEP20022653B (en) 2002-03-25
DE60032275T2 (de) 2007-07-12
NO20054715L (no) 2000-10-02
AU781402B2 (en) 2005-05-19
SK287339B6 (sk) 2010-07-07
AU2005201494A1 (en) 2005-05-05
ATE348098T1 (de) 2007-01-15
PT1044969E (pt) 2007-05-31
EG22506A (en) 2003-03-31
EP1044969A2 (en) 2000-10-18
HUP0001353A2 (hu) 2001-05-28
AP1655A (en) 2006-09-01
CA2427221C (en) 2008-09-16
AU2005201494B2 (en) 2008-02-07
EA200201245A1 (ru) 2003-04-24
DZ3030A1 (fr) 2004-03-27
GT200000037A (es) 2001-09-21
CO5160273A1 (es) 2002-05-30
UA70928C2 (uk) 2004-11-15
HU0001353D0 (en) 2000-06-28
AP2000001778A0 (en) 2000-03-31
AU2262000A (en) 2000-10-05
DE60032275D1 (de) 2007-01-25
EP1044969B1 (en) 2006-12-13
CZ20001155A3 (cs) 2001-03-14
NZ512818A (en) 2003-01-31
DK1044969T3 (da) 2007-04-23
BG65194B1 (bg) 2007-06-29
ZA200001586B (en) 2001-10-01
PA8491901A1 (es) 2001-12-14
US6476040B1 (en) 2002-11-05
HRP20000182B1 (en) 2007-10-31
IL168036A (en) 2006-12-10
BR0001486A (pt) 2001-05-02
TR200000837A2 (tr) 2000-11-21
SG121687A1 (en) 2006-05-26
CN100351242C (zh) 2007-11-28
ID25427A (id) 2000-10-05
IL135245A0 (en) 2001-05-20
KR20010014658A (ko) 2001-02-26
EA005561B1 (ru) 2005-04-28
YU13200A (sh) 2002-10-18
MY136270A (en) 2008-09-30
EP1044969A3 (en) 2000-11-29
UA80955C2 (en) 2007-11-26
CN1276370A (zh) 2000-12-13
AR018705A1 (es) 2001-11-28
CR6165A (es) 2008-10-10
IS5411A (is) 2000-10-02
EA200000274A2 (ru) 2000-10-30
UY26086A1 (es) 2000-10-31
SG115536A1 (en) 2005-10-28
CA2302965C (en) 2004-02-17
EE04589B1 (et) 2006-02-15
NO324745B1 (no) 2007-12-03
TNSN00064A1 (fr) 2005-11-10
AP1265A (en) 2004-03-26
SV2002000047A (es) 2002-01-23
HU227698B1 (en) 2011-12-28
EA004654B1 (ru) 2004-06-24

Similar Documents

Publication Publication Date Title
EG22506A (en) Processes and intermediates for preparing anti-cancer compounds
AP2003002757A0 (en) Process and intermediates for preparing anticancer compounds
IL145798A0 (en) Fap-activated anti-tumor compounds
EP1140083A4 (en) NEW CONNECTIONS
HUP0200448A3 (en) Processes for preparing pesticidal intermediates
GB9930390D0 (en) Releasable fasteners
EG24063A (en) Novel compounds
IL149007A0 (en) Pentacyclic taxane compounds
GB9924855D0 (en) Novel processes
HUP0201401A3 (en) Processes for preparing pesticidal intermediates
GB0121486D0 (en) Processes for the preparation of Α-Aminoketones
IL138691A (en) Process for the preparation of 3-acyl-indoles
HUP0202865A3 (en) Process for the preparation of 2-cyanopyridines
GB9923024D0 (en) Lap top extension
HUP0000559A3 (en) Process for preparing cyanoaceticacidesters
EP1242378A4 (en) NEW PROCEDURES
HUP0201518A3 (en) Process for the preparation of tetrafluorohalogenbenzenes
TW382910U (en) Structural improvement for the physique of the clog
GB0001064D0 (en) Structure for positioning stationery
IL140300A0 (en) Process for the preparation of amides
HU9904575D0 (en) Process for preparation of n-alkoxy-methyl-acidamides
TW404191U (en) Structure improvement for pendants
TW377550U (en) Improvement for grass-planting brick
TW385647U (en) Structure for ring
PL343301A1 (en) Fastening means

Legal Events

Date Code Title Description
AS Change of ownership

Owner name: PFIZER PRODUCTS INC.

Free format text: FORMER OWNER(S): PFIZER PRODUCTS INC

Owner name: OSI PHARMACEUTICALS, INC.

Free format text: FORMER OWNER(S): PFIZER PRODUCTS INC

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20110331